Subscribe to RSS
DOI: 10.1055/s-0038-1660437
Overcoming Heparin-Associated RT-qPCR Inhibition and Normalization Issues for microRNA Quantification in Patients with Acute Myocardial Infarction
Funding Jose Coelho-Lima is supported by a CAPES Foundation PhD scholarship (Brazilian Ministry of Education; BEX 0881–14–7). Ioakim Spyridopoulos is supported by grants from the British Heart Foundation as well as the Newcastle Health Care Charity and the Newcastle upon Tyne Hospitals NHS Charity.Publication History
11 January 2018
02 May 2018
Publication Date:
11 June 2018 (online)
Abstract
Background Cardiac-enriched micro ribonucleic acids (miRNAs) are released into the circulation following ST-elevation myocardial infarction (STEMI). Lack of standardized approaches for reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) data normalization and presence of RT-qPCR inhibitors (e.g. heparin) in patient blood samples have prevented reproducible miRNA quantification in this cohort and subsequent translation of these biomarkers to clinical practice.
Materials and Methods Using a RT-qPCR miRNA screening platform, we identified and validated an endogenous circulating miRNA as a normalization control. In addition, we assessed the effects of in vivo and in vitro anticoagulant drugs administration (heparin and bivalirudin) on three RT-qPCR normalization strategies (global miRNA mean, exogenous spike-in control [cel-miR-39] and endogenous miRNA control). Finally, we evaluated the effect of heparin and its in vitro inhibition with heparinase on the quantification of cardiac-enriched miRNAs in STEMI patients.
Results miR-425–5p was validated as an endogenous miRNA control. Heparin administration in vitro and in vivo inhibited all RT-qPCR normalization strategies. In contrast, bivalirudin had no effects on cel-miR-39 or miR-425–5p quantification. In vitro RNA sample treatment with 0.3 U of heparinase overcame heparin-induced over-estimation of cardiac-enriched miRNA levels and improved their correlation with high-sensitivity troponin T.
Conclusion miRNA quantification in STEMI patients receiving heparin is jeopardized by its effect on all RT-qPCR normalization approaches. Use of samples from bivalirudin-treated patients or in vitro treatment of heparin-contaminated samples with heparinase are suitable alternatives for miRNA quantification in this cohort. Finally, we reinforce the evidence that cardiac-enriched miRNAs early after myocardial reperfusion reflect the severity of cardiac injury.
-
References
- 1 Steg PG, James SK, Atar D. , et al; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33 (20) 2569-2619
- 2 van der Linden N, Streng AS, Bekers O, Wodzig WKWH, Meex SJR, de Boer D. Large variation in measured cardiac troponin T concentrations after standard addition in serum or plasma of different individuals. Clin Chem 2017; 63 (07) 1300-1302
- 3 Cobbaert CM, Bootsma M, Boden H. , et al. Confounding factors in the relation between high sensitivity cardiac troponin T levels in serum and infarct size of patients with first ST-elevation myocardial infarction. Int J Cardiol 2014; 172 (01) e3-e5
- 4 Mitchell PS, Parkin RK, Kroh EM. , et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105 (30) 10513-10518
- 5 Chen X, Ba Y, Ma L. , et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18 (10) 997-1006
- 6 Weber JA, Baxter DH, Zhang S. , et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56 (11) 1733-1741
- 7 Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB, Piper M. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med 2014; 18 (03) 371-390
- 8 Viereck J, Thum T. Circulating noncoding RNAs as biomarkers of cardiovascular disease and injury. Circ Res 2017; 120 (02) 381-399
- 9 Santovito D, Weber C. Zooming in on microRNAs for refining cardiovascular risk prediction in secondary prevention. Eur Heart J 2017; 38 (07) 524-528
- 10 Marabita F, de Candia P, Torri A, Tegnér J, Abrignani S, Rossi RL. Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR. Brief Bioinform 2016; 17 (02) 204-212
- 11 Boeckel JN, Thomé CE, Leistner D, Zeiher AM, Fichtlscherer S, Dimmeler S. Heparin selectively affects the quantification of microRNAs in human blood samples. Clin Chem 2013; 59 (07) 1125-1127
- 12 Kaudewitz D, Lee R, Willeit P. , et al. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb Haemost 2013; 110 (03) 609-615
- 13 Li S, Zhang F, Cui Y. , et al. Modified high-throughput quantification of plasma microRNAs in heparinized patients with coronary artery disease using heparinase. Biochem Biophys Res Commun 2017; 493 (01) 556-561
- 14 Mestdagh P, Van Vlierberghe P, De Weer A. , et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 2009; 10 (06) R64
- 15 Andersen CL, Jensen JL, Ørntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004; 64 (15) 5245-5250
- 16 Vandesompele J, De Preter K, Pattyn F. , et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3 (07) H0034
- 17 Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. Biotechnol Lett 2004; 26 (06) 509-515
- 18 Lippi G, Mattiuzzi C, Cervellin G. Circulating microRNAs (miRs) for diagnosing acute myocardial infarction: meta-analysis of available studies. Int J Cardiol 2013; 167 (01) 277-278
- 19 Ai J, Zhang R, Li Y. , et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010; 391 (01) 73-77
- 20 Wang F, Long G, Zhao C. , et al. Plasma microRNA-133a is a new marker for both acute myocardial infarction and underlying coronary artery stenosis. J Transl Med 2013; 11: 222
- 21 Zhang L, Chen X, Su T. , et al. Circulating miR-499 are novel and sensitive biomarker of acute myocardial infarction. J Thorac Dis 2015; 7 (03) 303-308
- 22 Zhang R, Lan C, Pei H, Duan G, Huang L, Li L. Expression of circulating miR-486 and miR-150 in patients with acute myocardial infarction. BMC Cardiovasc Disord 2015; 15: 51
- 23 Peng L, Chun-guang Q, Bei-fang L. , et al. Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma of patients with acute myocardial infarction. Diagn Pathol 2014; 9: 89
- 24 D'Alessandra Y, Devanna P, Limana F. , et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010; 31 (22) 2765-2773
- 25 Olivieri F, Antonicelli R, Lorenzi M. , et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol 2013; 167 (02) 531-536
- 26 Benz F, Roderburg C, Vargas Cardenas D. , et al. U6 is unsuitable for normalization of serum miRNA levels in patients with sepsis or liver fibrosis. Exp Mol Med 2013; 45: e42
- 27 McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 2011; 57 (06) 833-840
- 28 McDermott AM, Kerin MJ, Miller N. Identification and validation of miRNAs as endogenous controls for RQ-PCR in blood specimens for breast cancer studies. PLoS One 2013; 8 (12) e83718
- 29 Zhu M, Huang Z, Zhu D. , et al. A panel of microRNA signature in serum for colorectal cancer diagnosis. Oncotarget 2017; 8 (10) 17081-17091
- 30 Sun L, Jiang R, Li J. , et al. MicoRNA-425-5p is a potential prognostic biomarker for cervical cancer. Ann Clin Biochem 2017; 54 (01) 127-133
- 31 Di Pietro V, Ragusa M, Davies D. , et al. MicroRNAs as novel biomarkers for the diagnosis and prognosis of mild and severe traumatic brain injury. J Neurotrauma 2017; 34 (11) 1948-1956
- 32 Min PK, Kim JY, Chung KH. , et al. Local increase in microparticles from the aspirate of culprit coronary arteries in patients with ST-segment elevation myocardial infarction. Atherosclerosis 2013; 227 (02) 323-328
- 33 Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods 2015; 12 (08) 697
- 34 Panwar B, Omenn GS, Guan Y. miRmine: a database of human miRNA expression profiles. Bioinformatics 2017; 33 (10) 1554-1560
- 35 Gidlöf O, van der Brug M, Ohman J. , et al. Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression. Blood 2013; 121 (19) 3908-3917 , S1–S26
- 36 Mitchell AJ, Gray WD, Hayek SS. , et al. Platelets confound the measurement of extracellular miRNA in archived plasma. Sci Rep 2016; 6: 32651
- 37 Satsangi J, Jewell DP, Welsh K, Bunce M, Bell JI. Effect of heparin on polymerase chain reaction. Lancet 1994; 343 (8911): 1509-1510
- 38 Yokota M, Tatsumi N, Nathalang O, Yamada T, Tsuda I. Effects of heparin on polymerase chain reaction for blood white cells. J Clin Lab Anal 1999; 13 (03) 133-140
- 39 Turchinovich A, Burwinkel B. Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. RNA Biol 2012; 9 (08) 1066-1075
- 40 Johnson ML, Navanukraw C, Grazul-Bilska AT, Reynolds LP, Redmer DA. Heparinase treatment of RNA before quantitative real-time RT-PCR. Biotechniques 2003; 35 (06) 1140-1142 , 1144
- 41 Plieskatt JL, Feng Y, Rinaldi G, Mulvenna JP, Bethony JM, Brindley PJ. Circumventing qPCR inhibition to amplify miRNAs in plasma. Biomark Res 2014; 2: 13
- 42 Ibanez B, James S, Agewall S. , et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (02) 119-177
- 43 Gidlöf O, Andersson P, van der Pals J, Götberg M, Erlinge D. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology 2011; 118 (04) 217-226
- 44 Bauters C, Kumarswamy R, Holzmann A. , et al. Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. Int J Cardiol 2013; 168 (03) 1837-1840
- 45 Białek S, Górko D, Zajkowska A. , et al. Release kinetics of circulating miRNA-208a in the early phase of myocardial infarction. Kardiol Pol 2015; 73 (08) 613-619